Sinovac says H5N1 vaccine with adjuvant meets European requirements in trial

New York, Sept. 7 - Sinovac Biotech Ltd. said research published online by the Lancet showed that a two-dose regimen of an adjuvanted 10 ug inactivated whole-virion H5N1 vaccine met all European regulatory requirements for annual licensing of seasonal influenza vaccine.

Lower doses of the vaccine could achieve immune responses equivalent to those elicited by adjuvanted or non-adjuvanted split-virion vaccines, the research, conducted on 120 volunteers in China, found.

The use of a whole virion vaccine could be more adaptable to the antigen-sparing strategy recommended by the World Health Organization for protection against an influenza pandemic.

The study examined the safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine in a phase 1 trail, the Beijing-based biopharmaceutical company said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.